stoxline Quote Chart Rank Option Currency Glossary
  
Lineage Cell Therapeutics, Inc. (LCTX)
0.6702  -0.025 (-3.57%)    02-07 16:00
Open: 0.7
High: 0.7056
Volume: 744,556
  
Pre. Close: 0.695
Low: 0.665
Market Cap: 148(M)
Technical analysis
2025-02-07 4:45:37 PM
Short term     
Mid term     
Targets 6-month :  0.85 1-year :  0.99
Resists First :  0.73 Second :  0.85
Pivot price 0.64
Supports First :  0.58 Second :  0.5
MAs MA(5) :  0.68 MA(20) :  0.62
MA(100) :  0.72 MA(250) :  0.92
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  80.4 D(3) :  80.7
RSI RSI(14): 55.4
52-week High :  1.61 Low :  0.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LCTX ] has closed below upper band by 31.8%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.71 - 0.71 0.71 - 0.71
Low: 0.65 - 0.66 0.66 - 0.66
Close: 0.66 - 0.67 0.67 - 0.68
Company Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Headline News

Wed, 05 Feb 2025
BlackRock, Inc. Increases Stake in Lineage Cell Therapeutics Inc. - GuruFocus.com

Tue, 04 Feb 2025
Cell Therapy Pioneer Lineage to Showcase Latest Neurological Breakthroughs at Major Healthcare Conference - StockTitan

Tue, 04 Feb 2025
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference - Business Wire

Tue, 04 Feb 2025
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from HC Wainwright - MarketBeat

Mon, 27 Jan 2025
Lineage Cell Therapeutics Secures Additional $6M in Financing, Completes $30M Offering - StockTitan

Mon, 27 Jan 2025
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 189 (M)
Shares Float 146 (M)
Held by Insiders 0.4 (%)
Held by Institutions 50.3 (%)
Shares Short 15,820 (K)
Shares Short P.Month 14,560 (K)
Stock Financials
EPS -0.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.36
Profit Margin 0 %
Operating Margin -416.7 %
Return on Assets (ttm) -12.9 %
Return on Equity (ttm) -35.1 %
Qtrly Rev. Growth -56.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.03
EBITDA (p.s.) -0.12
Qtrly Earnings Growth 0 %
Operating Cash Flow -22 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -5.16
PEG Ratio 0
Price to Book value 1.86
Price to Sales 20.44
Price to Cash Flow -5.75
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android